Two mouse models produce anti-insulin antibodies with enhanced insulin binding capacity, and hence model accelerated TID disease progression. A third mouse model features altered VDJ sequence in the immunoglobulin heavy chain (VH281 Tg line) which produces the non-insulin binding mutant version of the anti-insulin antibody mAB 125, which models reduced disease progression and severity. Hence these mice can be very useful tools in investigating TID disease mechanism as well as potential therapeutics.
